Chief Executive Officer
Jonathan is a life sciences executive with more than 25 years of experience in biotechnology management. He previously served as Chief Business Officer of PhaseBio. Prior to PhaseBio, Jonathan served as Vice President, Business Development for Amylin Pharmaceuticals from 2007 until its sale to Bristol-Myers Squibb in 2012. Jonathan was co-founder and Vice President, Commercial and Business Development of Corus Pharma, Inc., until its acquisition by Gilead Sciences in 2006. Earlier in his career, he led the business development efforts for PathoGenesis Corporation, culminating in the company’s acquisition by Chiron Corporation in 2000. Jonathan has held positions in sales and marketing at Bristol-Myers Squibb, Wyeth / Lederle International and Syntex Laboratories. Jonathan received a BS in Mechanical Engineering from the University of California, Berkeley and an MBA from the Carnegie Mellon University Tepper School of Business.